Association between maternal serum alpha-fetoprotein and adverse outcomes in pregnancies with placenta previa

Erin L. Butler, Jodi S. Dashe, Ronald M. Ramus

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To determine whether increased maternal serum alpha-fetoprotein (MSAFP) level at 15-20 weeks' gestation is a marker of adverse outcomes in women with placenta previa at delivery. Methods: We conducted a retrospective cohort study of singleton pregnancies complicated by placenta previa, diagnosed sonographically, and confirmed at delivery. All women had MSAFP screening at 15-20 weeks' gestation and delivered nonanomalous live-born infants at or after 24 weeks' gestation. Results: One hundred seven women with placenta previa delivered during the study. Fourteen (13%, 95% CI 7%, 21%) had MSAFP at least 2.0 multiples of the median (MoM). They were significantly more likely than those with lower MSAFP levels to have one or more of the following outcomes: hospitalization for antepartum bleeding before 30 weeks' gestation (50% versus 15%), delivery before 30 weeks' gestation (29% versus 5%), or preterm delivery for pregnancy-associated hypertension before 34 weeks' gestation (14% versus none). The MSAFP cutoff of 2.0 MoM provided the best combination of sensitivity and specificity for those outcomes, using receiver operating characteristic curves. Conclusion: Women with placenta previa who also have high MSAFP levels are at increased risk of bleeding in the early third trimester and preterm birth. We did not find women who required cesarean hysterectomy, including those with placenta accreta, to consistently have elevated MSAFP.

Original languageEnglish (US)
Pages (from-to)35-38
Number of pages4
JournalObstetrics and Gynecology
Volume97
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Placenta Previa
alpha-Fetoproteins
Pregnancy Outcome
Mothers
Pregnancy
Serum
Placenta Accreta
Hemorrhage
Premature Birth
Third Pregnancy Trimester
Hysterectomy
ROC Curve
Hospitalization
Cohort Studies
Retrospective Studies
Hypertension
Sensitivity and Specificity

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Association between maternal serum alpha-fetoprotein and adverse outcomes in pregnancies with placenta previa. / Butler, Erin L.; Dashe, Jodi S.; Ramus, Ronald M.

In: Obstetrics and Gynecology, Vol. 97, No. 1, 2001, p. 35-38.

Research output: Contribution to journalArticle

@article{5d8ddd7f61e8429699e65f345d6b109e,
title = "Association between maternal serum alpha-fetoprotein and adverse outcomes in pregnancies with placenta previa",
abstract = "Objective: To determine whether increased maternal serum alpha-fetoprotein (MSAFP) level at 15-20 weeks' gestation is a marker of adverse outcomes in women with placenta previa at delivery. Methods: We conducted a retrospective cohort study of singleton pregnancies complicated by placenta previa, diagnosed sonographically, and confirmed at delivery. All women had MSAFP screening at 15-20 weeks' gestation and delivered nonanomalous live-born infants at or after 24 weeks' gestation. Results: One hundred seven women with placenta previa delivered during the study. Fourteen (13{\%}, 95{\%} CI 7{\%}, 21{\%}) had MSAFP at least 2.0 multiples of the median (MoM). They were significantly more likely than those with lower MSAFP levels to have one or more of the following outcomes: hospitalization for antepartum bleeding before 30 weeks' gestation (50{\%} versus 15{\%}), delivery before 30 weeks' gestation (29{\%} versus 5{\%}), or preterm delivery for pregnancy-associated hypertension before 34 weeks' gestation (14{\%} versus none). The MSAFP cutoff of 2.0 MoM provided the best combination of sensitivity and specificity for those outcomes, using receiver operating characteristic curves. Conclusion: Women with placenta previa who also have high MSAFP levels are at increased risk of bleeding in the early third trimester and preterm birth. We did not find women who required cesarean hysterectomy, including those with placenta accreta, to consistently have elevated MSAFP.",
author = "Butler, {Erin L.} and Dashe, {Jodi S.} and Ramus, {Ronald M.}",
year = "2001",
doi = "10.1016/S0029-7844(00)01095-4",
language = "English (US)",
volume = "97",
pages = "35--38",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Association between maternal serum alpha-fetoprotein and adverse outcomes in pregnancies with placenta previa

AU - Butler, Erin L.

AU - Dashe, Jodi S.

AU - Ramus, Ronald M.

PY - 2001

Y1 - 2001

N2 - Objective: To determine whether increased maternal serum alpha-fetoprotein (MSAFP) level at 15-20 weeks' gestation is a marker of adverse outcomes in women with placenta previa at delivery. Methods: We conducted a retrospective cohort study of singleton pregnancies complicated by placenta previa, diagnosed sonographically, and confirmed at delivery. All women had MSAFP screening at 15-20 weeks' gestation and delivered nonanomalous live-born infants at or after 24 weeks' gestation. Results: One hundred seven women with placenta previa delivered during the study. Fourteen (13%, 95% CI 7%, 21%) had MSAFP at least 2.0 multiples of the median (MoM). They were significantly more likely than those with lower MSAFP levels to have one or more of the following outcomes: hospitalization for antepartum bleeding before 30 weeks' gestation (50% versus 15%), delivery before 30 weeks' gestation (29% versus 5%), or preterm delivery for pregnancy-associated hypertension before 34 weeks' gestation (14% versus none). The MSAFP cutoff of 2.0 MoM provided the best combination of sensitivity and specificity for those outcomes, using receiver operating characteristic curves. Conclusion: Women with placenta previa who also have high MSAFP levels are at increased risk of bleeding in the early third trimester and preterm birth. We did not find women who required cesarean hysterectomy, including those with placenta accreta, to consistently have elevated MSAFP.

AB - Objective: To determine whether increased maternal serum alpha-fetoprotein (MSAFP) level at 15-20 weeks' gestation is a marker of adverse outcomes in women with placenta previa at delivery. Methods: We conducted a retrospective cohort study of singleton pregnancies complicated by placenta previa, diagnosed sonographically, and confirmed at delivery. All women had MSAFP screening at 15-20 weeks' gestation and delivered nonanomalous live-born infants at or after 24 weeks' gestation. Results: One hundred seven women with placenta previa delivered during the study. Fourteen (13%, 95% CI 7%, 21%) had MSAFP at least 2.0 multiples of the median (MoM). They were significantly more likely than those with lower MSAFP levels to have one or more of the following outcomes: hospitalization for antepartum bleeding before 30 weeks' gestation (50% versus 15%), delivery before 30 weeks' gestation (29% versus 5%), or preterm delivery for pregnancy-associated hypertension before 34 weeks' gestation (14% versus none). The MSAFP cutoff of 2.0 MoM provided the best combination of sensitivity and specificity for those outcomes, using receiver operating characteristic curves. Conclusion: Women with placenta previa who also have high MSAFP levels are at increased risk of bleeding in the early third trimester and preterm birth. We did not find women who required cesarean hysterectomy, including those with placenta accreta, to consistently have elevated MSAFP.

UR - http://www.scopus.com/inward/record.url?scp=0035173717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035173717&partnerID=8YFLogxK

U2 - 10.1016/S0029-7844(00)01095-4

DO - 10.1016/S0029-7844(00)01095-4

M3 - Article

VL - 97

SP - 35

EP - 38

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -